Albany Molecular Research, Inc. (AMRI) Announces First Quarter 2014 Results
Published: May 06, 2014
ALBANY, New York, May 06, 2014 (PR Newswire Europe via COMTEX) -- -- Contract Revenue Growth of 10% to $51.0 Million and Adjusted Diluted EPS of $0.16
-- Company Increases 2014 Adjusted EPS Guidance to $0.78 - $0.84 to Reflect Addition of Cedarburg Pharmaceuticals and Strengthening Contract Business
Help employers find you! Check out all the jobs and post your resume.